优化再灌注试验:STAIR XIII会议共识研究路线图
2025年3月27至28日,STAIR XIII会议在华盛顿召开再灌注治疗专题研讨会,汇集卒中神经科医师、神经放射科医师、神经影像研究科学家、NINDS成员及业界代表,比较近期急性卒中试验并形成研究优先级与试验设计的共识推荐。会议将建立可在转运场景开展试验的研究网络列为核心优先事项,并聚焦微血管再灌注与无复流现象的定义与研究。
要点
- 多数适合再灌注治疗的患者首诊于初级卒中中心,应建立支持转运场景开展试验的研究网络。
- 微血管再灌注与无复流现象的定义及研究是重点方向。
- 未来试验在初级与综合卒中中心的招募面临挑战,尤其对新型溶栓药物而言。
核心结论
- 会议形成关于再灌注治疗研究优先级与试验设计要素的共识推荐,强调转运场景研究网络建设及微血管再灌注与无复流现象研究。
研究设计与样本
- STAIR XIII会议于2025年3月27至28日在华盛顿召开再灌注治疗专题研讨会,参会者包括卒中神经科医师、神经放射科医师、神经影像研究科学家、NINDS成员及业界代表,以形成共识推荐。
主要发现
- 近期急性卒中临床试验扩展了静脉溶栓与血管内取栓的适用范围。
- 多数适合再灌注治疗的患者首诊于初级卒中中心,在转运场景开展试验并克服此类中心的后勤挑战被确定为核心优先事项。
- 会议聚焦微血管再灌注与无复流现象的定义与研究,并讨论了推进该领域的潜在试验范式。
- 未来试验在初级与综合卒中中心于标准治疗之上开展招募面临挑战,尤其对新型溶栓药物而言。
关键数值与推荐
- 会议提供了加强卒中影像研究以及界定大血管再灌注与微血管再灌注的推荐。
临床怎么用
- 未来再灌注试验设计可考虑在转运场景及初级卒中中心布局研究网络,并将微血管再灌注与无复流作为研究重点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The STAIR (Stroke Treatment Academic Industry Roundtable) sponsored a workshop during the STAIR XIII conference in Washington, DC on March 27 to 28, 2025, to develop consensus recommendations, particularly regarding research priorities and design elements for trials of reperfusion therapies. This forum brought together stroke neurologists, neuroradiologists, neuroimaging research scientists, members of the National Institute of Neurological Disorders and Stroke, and industry representatives to discuss future developments in reperfusion therapies. The reperfusion trials session summarized and compared recent acute stroke trials. The workshop developed consensus recommendations for research priorities and trial design challenges. Given that the majority of patients eligible for reperfusion therapies present initially to primary stroke centers, developing research networks that allow trials to be conducted in the transfer setting and overcome the logistical challenges in such centers was identified as a key priority. A particular focus was the definition and investigation of microvascular reperfusion and the no-reflow phenomenon. Potential trial paradigms to advance the field were discussed. Recent acute stroke clinical trials have extended the scope of intravenous thrombolytics and endovascular thrombectomy. Recruitment for future trials at both primary and comprehensive stroke centers, in addition to standard of care, poses challenges, particularly for novel thrombolytics. Recommendations for enhancing stroke imaging research and the definition of macrovascular versus microvascular reperfusion are provided.
引用
- Campbell BCV, Aziz YN, Harston GWJ, et al. Optimizing Reperfusion Trials: A Consensus Research Roadmap From the STAIR XIII Conference. Stroke. 2025. PMID: 41235436. doi:10.1161/STROKEAHA.125.052148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。